FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022703205> ?p ?o ?g. }

• W2022703205 endingPage "63" @default.
• W2022703205 startingPage "57" @default.
• W2022703205 abstract "Background:The common treatment for antineutrophil cytoplasmic autoantibody (ANCA)–associated renal vasculitis is oral cyclophosphamide (CYC)-corticosteroid combination therapy. However, there are serious complications associated with long-term use of CYC. In this study, we investigate the efficacy of a purine synthesis inhibitor, mizoribine, for patients at high risk for relapse. Methods:Our study included 5 patients, 4 patients with myeloperoxidase (MPO)-ANCA-associated renal vasculitis and 1 patient with proteinase 3 (PR3)-ANCA-associated renal vasculitis, who had achieved remission through treatment with methylprednisolone pulse therapy, corticosteroids, and CYC. When their ANCA titers were found to be greater than normal range after remission status, mizoribine treatment was initiated. Results:Median time from initial treatment to first administration of mizoribine was 40.0 months (range, 24 to 51 months). Median follow-up was 13.0 months (range, 6 to 16 months). Before initiation of mizoribine treatment, no patient had experienced relapse and ANCA titers were less than the detectable range in all patients at 3 months before mizoribine administration. When mizoribine administration was started, ANCA titers were elevated in all patients (median MPO-ANCA, 101 ELISA units [EU]; range, 65 to 154 EU; PR3-ANCA, 55 EU), but no new symptoms or signs of relapse were noted. After 2 months of mizoribine treatment, only 1 patient had experienced a relapse; however, ANCA titers had decreased in all other patients and normalized in 3 patients. No adverse effects appeared in any patient. Conclusion:Considering the balance between suppression of disease activity and adverse effects of treatment, mizoribine may be useful for preemptive treatment for patients with ANCA-associated renal vasculitis at high risk for relapse." @default.
• W2022703205 created "2016-06-24" @default.
• W2022703205 creator A5008105978 @default.
• W2022703205 creator A5011751860 @default.
• W2022703205 creator A5041641555 @default.
• W2022703205 creator A5045347848 @default.
• W2022703205 creator A5048496043 @default.
• W2022703205 creator A5053416358 @default.
• W2022703205 creator A5057313515 @default.
• W2022703205 creator A5067940910 @default.
• W2022703205 creator A5069336850 @default.
• W2022703205 creator A5076738026 @default.
• W2022703205 creator A5079821787 @default.
• W2022703205 date "2004-07-01" @default.
• W2022703205 modified "2023-10-15" @default.
• W2022703205 title "Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis" @default.
• W2022703205 cites W1981535363 @default.
• W2022703205 cites W1982754000 @default.
• W2022703205 cites W2006726784 @default.
• W2022703205 cites W2021397728 @default.
• W2022703205 cites W2022905351 @default.
• W2022703205 cites W2032088849 @default.
• W2022703205 cites W2033008576 @default.
• W2022703205 cites W2044732270 @default.
• W2022703205 cites W2078438260 @default.
• W2022703205 cites W2093832398 @default.
• W2022703205 cites W2102454572 @default.
• W2022703205 cites W2124203673 @default.
• W2022703205 cites W2132174947 @default.
• W2022703205 cites W2140547944 @default.
• W2022703205 cites W2149200961 @default.
• W2022703205 cites W2150612435 @default.
• W2022703205 cites W2152588489 @default.
• W2022703205 cites W2264075806 @default.
• W2022703205 cites W2581458651 @default.
• W2022703205 doi "https://doi.org/10.1053/j.ajkd.2004.03.030" @default.
• W2022703205 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15211438" @default.
• W2022703205 hasPublicationYear "2004" @default.
• W2022703205 type Work @default.
• W2022703205 sameAs 2022703205 @default.
• W2022703205 citedByCount "34" @default.
• W2022703205 countsByYear W20227032052012 @default.
• W2022703205 countsByYear W20227032052013 @default.
• W2022703205 countsByYear W20227032052014 @default.
• W2022703205 countsByYear W20227032052017 @default.
• W2022703205 countsByYear W20227032052018 @default.
• W2022703205 countsByYear W20227032052019 @default.
• W2022703205 countsByYear W20227032052022 @default.
• W2022703205 countsByYear W20227032052023 @default.
• W2022703205 crossrefType "journal-article" @default.
• W2022703205 hasAuthorship W2022703205A5008105978 @default.
• W2022703205 hasAuthorship W2022703205A5011751860 @default.
• W2022703205 hasAuthorship W2022703205A5041641555 @default.
• W2022703205 hasAuthorship W2022703205A5045347848 @default.
• W2022703205 hasAuthorship W2022703205A5048496043 @default.
• W2022703205 hasAuthorship W2022703205A5053416358 @default.
• W2022703205 hasAuthorship W2022703205A5057313515 @default.
• W2022703205 hasAuthorship W2022703205A5067940910 @default.
• W2022703205 hasAuthorship W2022703205A5069336850 @default.
• W2022703205 hasAuthorship W2022703205A5076738026 @default.
• W2022703205 hasAuthorship W2022703205A5079821787 @default.
• W2022703205 hasConcept C126322002 @default.
• W2022703205 hasConcept C159654299 @default.
• W2022703205 hasConcept C163764329 @default.
• W2022703205 hasConcept C197934379 @default.
• W2022703205 hasConcept C203014093 @default.
• W2022703205 hasConcept C2776015282 @default.
• W2022703205 hasConcept C2776694085 @default.
• W2022703205 hasConcept C2776755627 @default.
• W2022703205 hasConcept C2777882293 @default.
• W2022703205 hasConcept C2779134260 @default.
• W2022703205 hasConcept C71924100 @default.
• W2022703205 hasConcept C90924648 @default.
• W2022703205 hasConceptScore W2022703205C126322002 @default.
• W2022703205 hasConceptScore W2022703205C159654299 @default.
• W2022703205 hasConceptScore W2022703205C163764329 @default.
• W2022703205 hasConceptScore W2022703205C197934379 @default.
• W2022703205 hasConceptScore W2022703205C203014093 @default.
• W2022703205 hasConceptScore W2022703205C2776015282 @default.
• W2022703205 hasConceptScore W2022703205C2776694085 @default.
• W2022703205 hasConceptScore W2022703205C2776755627 @default.
• W2022703205 hasConceptScore W2022703205C2777882293 @default.
• W2022703205 hasConceptScore W2022703205C2779134260 @default.
• W2022703205 hasConceptScore W2022703205C71924100 @default.
• W2022703205 hasConceptScore W2022703205C90924648 @default.
• W2022703205 hasIssue "1" @default.
• W2022703205 hasLocation W20227032051 @default.
• W2022703205 hasLocation W20227032052 @default.
• W2022703205 hasOpenAccess W2022703205 @default.
• W2022703205 hasPrimaryLocation W20227032051 @default.
• W2022703205 hasRelatedWork W1972230880 @default.
• W2022703205 hasRelatedWork W1992299009 @default.
• W2022703205 hasRelatedWork W2017491488 @default.
• W2022703205 hasRelatedWork W2022703205 @default.
• W2022703205 hasRelatedWork W2035341095 @default.
• W2022703205 hasRelatedWork W2132657197 @default.
• W2022703205 hasRelatedWork W2133423368 @default.
• W2022703205 hasRelatedWork W2437876400 @default.

• next